Compare URGN & WABC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | URGN | WABC |
|---|---|---|
| Founded | 2004 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2017 | N/A |
| Metric | URGN | WABC |
|---|---|---|
| Price | $21.96 | $48.97 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | $28.50 | ★ $52.00 |
| AVG Volume (30 Days) | ★ 998.4K | 116.9K |
| Earning Date | 11-06-2025 | 01-15-2026 |
| Dividend Yield | N/A | ★ 3.76% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.59 |
| Revenue | $96,516,000.00 | ★ $264,660,000.00 |
| Revenue This Year | $27.96 | N/A |
| Revenue Next Year | $123.02 | N/A |
| P/E Ratio | ★ N/A | $10.67 |
| Revenue Growth | ★ 8.00 | N/A |
| 52 Week Low | $3.42 | $42.00 |
| 52 Week High | $30.00 | $56.83 |
| Indicator | URGN | WABC |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 56.53 |
| Support Level | $21.74 | $46.93 |
| Resistance Level | $30.00 | $49.50 |
| Average True Range (ATR) | 1.56 | 1.19 |
| MACD | -0.72 | 0.10 |
| Stochastic Oscillator | 3.15 | 67.26 |
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Westamerica Bancorp is based in San Rafael, California. Westamerica Bancorporation runs a regional community bank and has approximately $7.5 billion in assets. The banks' net revenue is generated by net interest income. Deposit service charges make up the noninterest income sources. The bank focuses mostly on commercial clients, such as smaller businesses. Its footprint encompasses central and northern California, extending north of San Francisco to Mendocino and Lake counties, south to Kern County in central California and all the way east to Nevada County.